Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hepatorenal Syndrome
- Sponsor
- The University of Hong Kong
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Hepatorenal syndrome
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers investigated include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.
Detailed Description
This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers tested include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.
Investigators
Dr. Desmond Yat-Hin Yap
Clinical Assistant Professor
The University of Hong Kong
Eligibility Criteria
Inclusion Criteria
- •Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation
- •Willing to give informed consent
Exclusion Criteria
- •Patients with co-existing renal diseases
Outcomes
Primary Outcomes
Hepatorenal syndrome
Time Frame: 12 weeks
Secondary Outcomes
- Mortality(6 months)
- Chronic renal impairment(6 months)